Verinnogen named one of Cofinitive 21 to Watch
Congratulations to portfolio company Verinnogen for making the Cofinitive #21toWatch, Top 21 for 2024!
This is great recognition of the Verinnogen team's work to help transform pre-clinical oncology research with their innovative device for measuring physical properties of 3D surfaces.
Isaac Johnson, CEO and Co-Founder said: “Verinnogen exists to bring new enabling technologies to under-served scientific sectors, starting with this conceptually simple but brilliantly innovative tool to improve the way new cancer therapies are assessed in vivo, getting early-stage, transformative treatments through to clinical trials, and patients, faster.
“We’re grateful for this recognition, and to all our partners, for helping us highlight that better tools means better science.”